MilliporeSigma Unveils New State-of-the-Art M Lab™ Collaboration Center in Korea

• Provides customer support and collaboration from pre-clinical through full-scale production in a non-GMP environment
• Hands-on customer access to MilliporeSigma’s product portfolio, technical expertise
• Manufacturing simulations encompass full end-to-end process development

Billerica, Massachusetts, October 6, 2016 — MilliporeSigma today announced the opening of an M Lab™ Collaboration Center in the Songdo district of Incheon, Korea, one of the fastest growing biotech hubs in Asia. The center provides biopharmaceutical manufacturers with a shared, exploratory environment where they can closely collaborate with MilliporeSigma scientists and engineers to accelerate development and production of new therapies.

“With a rapidly growing biopharmaceutical industry in Korea and demand for novel and cost-effective therapies worldwide, there is a clear need for innovative concepts like our M Lab™ Collaboration Centers,” said Udit Batra, CEO, MilliporeSigma. “At our new center in Incheon, our customers will benefit from our deep technical expertise to develop processes for manufacturing drugs faster, safer and more effectively than ever before.”

The new M Lab™ Collaboration Center replaces a smaller facility in Seoul and will better suit the needs of Korea’s growing biopharmaceutical market. The new, state-of-the art center will include a simulated manufacturing environment and offer full end-to-end process development support. In addition, education on best practices and new approaches to develop, optimize and scale-up processes and simplify global technology transfer will be available to customers.

With 1,865 square meters of space and more than ten highly trained scientists and engineers, the M Lab™ Collaboration Center will serve local biopharma manufacturers, spanning the spectrum from multinational organizations like Samsung Biologics to emerging companies developing biologics to treat rare diseases or different types of cancer.

“The new M Lab™ Collaboration Center will play a great role in providing technical support and training of Korean biopharmaceutical employees,” said TH Kim, CEO of Samsung BioLogics. “MilliporeSigma’s decision to invest in Songdo, fast growing as world largest biologics manufacturing hub with 520 KL of plant capacity by 2018, represents a significant milestone in the development of the Songdo Bio Cluster, which will accelerate the future growth of Incheon as well as Korean Biopharmaceutical industry.”

The new M Lab™ Collaboration Center in Incheon is one of nine such centers around the world. Each center allows pharmaceutical manufacturers to explore new ways to increase productivity, improve processes and mitigate risks by giving them access to a world-class team of experts. Customers have access to sizing and simulation tools and methodologies as well as analytical and modeling support. Formal bioprocessing educational courses are also available, including traditional classroom-style training and interactive, hands-on sessions.

The inauguration ceremony was attended by Stephan Auer (German Ambassador), Prof. Dr. Gerhard Sabathil (Ambassador & Head of Delegation of the European Union to the Republic of Korea), Seung Tack Park (Director General for Investment Policy, Ministry of Trade, Industry and Energy), Dr. Jeong Bok Yoo (Mayor of Incheon Metropolitan City), Young Geun Lee (Commissioner, Incheon City government), Dr. Frank Stangenberg-Haverkamp (Chairman of the Executive Board and the Family Board, E. Merck KG) and Dr. Udit Batra (CEO, MilliporeSigma).

About the Life Science Business of Merck KGaA, Darmstadt, Germany
The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 19,000 employees and 65 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.

Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.

Merck KGaA of Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of €12.85 billion in 2015. Around 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.

Merck KGaA, Darmstadt, Germany is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck KGaA, Darmstadt, Germany holds the global rights to the name and the trademark “Merck” internationally except for the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.